SCHEDULE: Empery Asset Management Discloses 9.99% Stake in Precision BioSciences

Empery Asset Management, LP and Ryan M. Lane have reported a 9.99% beneficial ownership stake in Precision BioSciences, Inc., including shares from warrants, as of December 31, 2025.

Summary

• Empery Asset Management, LP and Ryan M. Lane collectively reported beneficial ownership of 2,297,781 shares of Precision BioSciences, Inc. Common Stock.
• This ownership represents 9.99% of the company's outstanding Common Stock.
• The reported shares include 103,146 shares issuable upon the exercise of warrants.
• A 'Blocker' provision prevents the Reporting Persons from exercising warrants if it would cause their beneficial ownership to exceed 9.99% of the outstanding shares.
• The calculation is based on 22,897,665 shares of Common Stock outstanding as of November 10, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Precision BioSciences, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake (9.99%) is generally positive as it signals investor confidence. However, the 'Blocker' provision limiting further warrant exercise introduces a slight constraint on potential future accumulation via warrants, preventing a higher score.

Positives

• A significant institutional investor, Empery Asset Management, has taken a substantial stake in Precision BioSciences, indicating potential confidence in the company's future.

Negatives

• The 'Blocker' provision limits the ability of Empery Asset Management to increase its stake beyond 9.99% through warrant exercise, potentially capping immediate upside from further accumulation via warrants.

Risks

• The 'Blocker' provision restricts the Reporting Persons from exercising warrants if it would lead to beneficial ownership exceeding 9.99% of the outstanding shares, which could limit their flexibility in increasing their stake.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Precision BioSciences, Inc. It primarily reports a change in beneficial ownership by an institutional investor.

Management Comments

• The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing indicates an institutional investor's significant stake in a biotechnology company, Precision BioSciences, Inc., which operates in a sector often characterized by high growth potential and significant capital requirements. Such a substantial stake by an asset manager like Empery Asset Management could be viewed as a vote of confidence in the company's long-term prospects or its specific therapeutic pipeline, aligning with broader trends of institutional interest in innovative biotech firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake may be viewed positively, potentially increasing investor confidence and market liquidity.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the stake is not for control purposes.

Key Dates

Recommendation

The filing indicates a substantial institutional investment by Empery Asset Management, LP, suggesting a degree of confidence in Precision BioSciences. While this is a positive signal, the filing itself is a disclosure of ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. The 'Blocker' provision also limits the immediate upside from further warrant exercises by this specific investor. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while awaiting further operational updates or financial results from Precision BioSciences.

Keywords

Precision BioSciences, Empery Asset Management, Ryan M. Lane, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Biotechnology, SEC Filing